IL94460A0 - Pharmaceutical compositions containing imipramine or derivatives thereof - Google Patents

Pharmaceutical compositions containing imipramine or derivatives thereof

Info

Publication number
IL94460A0
IL94460A0 IL94460A IL9446090A IL94460A0 IL 94460 A0 IL94460 A0 IL 94460A0 IL 94460 A IL94460 A IL 94460A IL 9446090 A IL9446090 A IL 9446090A IL 94460 A0 IL94460 A0 IL 94460A0
Authority
IL
Israel
Prior art keywords
pharmaceutical compositions
pct
derivatives
compositions containing
imipramine
Prior art date
Application number
IL94460A
Other languages
English (en)
Original Assignee
Rhone Poulenc Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Sante filed Critical Rhone Poulenc Sante
Publication of IL94460A0 publication Critical patent/IL94460A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Filtering Materials (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL94460A 1989-05-24 1990-05-21 Pharmaceutical compositions containing imipramine or derivatives thereof IL94460A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8906781A FR2647343B1 (fr) 1989-05-24 1989-05-24 Nouvelle forme pharmaceutique poreuse et sa preparation

Publications (1)

Publication Number Publication Date
IL94460A0 true IL94460A0 (en) 1991-03-10

Family

ID=9381955

Family Applications (2)

Application Number Title Priority Date Filing Date
IL9445990A IL94459A (en) 1989-05-24 1990-05-21 Pharmaceutical form and process for its preparation
IL94460A IL94460A0 (en) 1989-05-24 1990-05-21 Pharmaceutical compositions containing imipramine or derivatives thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL9445990A IL94459A (en) 1989-05-24 1990-05-21 Pharmaceutical form and process for its preparation

Country Status (24)

Country Link
US (1) US5244881A (no)
EP (2) EP0399902B1 (no)
JP (1) JP2948271B2 (no)
KR (1) KR0163423B1 (no)
AT (2) ATE98867T1 (no)
AU (2) AU623779B2 (no)
CA (2) CA2017360A1 (no)
DD (1) DD297915A5 (no)
DE (2) DE69000641T2 (no)
DK (2) DK0399903T3 (no)
ES (2) ES2062437T3 (no)
FI (1) FI103712B1 (no)
FR (1) FR2647343B1 (no)
GR (1) GR3006655T3 (no)
IE (2) IE64370B1 (no)
IL (2) IL94459A (no)
NO (1) NO180517C (no)
NZ (2) NZ233766A (no)
PL (1) PL285327A1 (no)
PT (2) PT94139B (no)
TW (1) TW257672B (no)
WO (1) WO1990014089A1 (no)
YU (1) YU100790A (no)
ZA (2) ZA903895B (no)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519428B1 (en) * 1991-06-21 2000-09-20 Takeda Chemical Industries, Ltd. Cyclodextrin compositions with fumagillol derivates
AU666509B2 (en) 1991-12-24 1996-02-15 Yamanouchi Pharmaceutical Co., Ltd. Intrabuccally disintegrating preparation and production thereof
GB9318880D0 (en) * 1993-09-11 1993-10-27 Smithkline Beecham Plc Pharmaceutical composition
AU2531295A (en) * 1994-05-27 1995-12-21 Farmarc Nederland Bv Pharmaceutical composition
WO1998036738A1 (en) * 1997-02-20 1998-08-27 Therics, Inc. Dosage form exhibiting rapid disperse properties, methods of use and process for the manufacture of same
BE1011251A3 (fr) 1997-07-03 1999-06-01 Ucb Sa Compositions pharmaceutiques administrables par voie orale, comprenant une substance active et une cyclodextrine.
TW527195B (en) 1997-10-09 2003-04-11 Ssp Co Ltd Fast-soluble solid pharmaceutical combinations
NZ506389A (en) * 1998-02-05 2003-07-25 Novartis Ag Pharmaceutical compositions containing epothilone which can be optionally lyophilised
IT1304190B1 (it) * 1998-12-18 2001-03-08 Euphar Group Srl Clatrati di deidroepiandrosterone e relative composizionifarmaceutiche
US6287603B1 (en) * 1999-09-16 2001-09-11 Nestec S.A. Cyclodextrin flavor delivery systems
CN101632642B (zh) 2002-01-15 2011-06-08 Ucb法奇姆股份有限公司 口感和稳定性改善的配方
IL163685A0 (en) 2002-02-25 2005-12-18 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
DE10239531A1 (de) * 2002-08-23 2004-03-04 Gulbins, Erich, Prof. Dr. Prophylaxe und Therapie von Infektionserkrankungen
DE10248314A1 (de) * 2002-10-16 2004-04-29 Dr. Suwelack Skin & Health Care Ag Verwendung von Formkörpern zur äußeren Anwendung
FR2876910B1 (fr) * 2004-10-21 2007-04-13 Pierre Fabre Medicament Sa Complexe comprenant la mequitazine, une cyclodextrine et un agent d'interaction
EA017982B1 (ru) 2005-02-24 2013-04-30 ДИФФЬЮЖН ФАРМАСЬЮТИКАЛЗ ЭлЭлСи Фармацевтическая композиция на основе транскаротиноидов и способы лечения опухоли
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
EP2146948A4 (en) 2007-04-13 2010-08-04 Diffusion Pharmaceuticals Llc USE OF BIPOLAR TRANS-CAROTINOIDES AS PRE-TREATMENT AND TREATMENT OF PERIPHERAL VASCULAR DISEASE
JP2009091309A (ja) * 2007-10-10 2009-04-30 Japan Organo Co Ltd バコパモニエラエキスを含有する組成物およびその製造方法ならびに飲食品
AU2008319225B2 (en) 2007-10-31 2016-09-29 Diffusion Pharmaceuticals Llc A new class of therapeutics that enhance small molecule diffusion
RU2011112926A (ru) * 2008-09-05 2012-10-10 МакНЕЙЛ-ППС, ИНК. (US) Способ изготовления таблеток цетиризина
US10130689B2 (en) 2009-06-22 2018-11-20 Diffusion Pharmaceuticals Llc Diffusion enhancing compounds and their use alone or with thrombolytics
EP2575487B1 (en) 2010-06-02 2017-10-18 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
NZ608239A (en) * 2010-09-13 2015-05-29 Bev Rx Inc Aqueous drug delivery system comprising off - flavor masking agent
RU2609198C1 (ru) * 2016-01-25 2017-01-30 Закрытое Акционерное Общество "БИОКОМ" Твердая лекарственная форма имипрамина немедленного высвобождения и способ ее получения
EP3432929A4 (en) 2016-03-24 2019-11-27 Diffusion Pharmaceuticals LLC USE OF BIPOLAR TRANSCAROTINOIDS WITH CHEMOTHERAPY AND RADIOTHERAPY FOR THE TREATMENT OF CANCER

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5443570B2 (no) * 1972-10-27 1979-12-20
IE45770B1 (en) * 1976-10-06 1982-11-17 Wyeth John & Brother Ltd Pharmaceutical dosage forms
US4165382A (en) * 1977-10-17 1979-08-21 Jose Pozuelo Method of pharmacologically treating schizophrenia with alpha-methyl-para-tyrosine
US4349472A (en) * 1979-04-27 1982-09-14 Schering Corporation (S)-8(1-Adamantanecarbonyloxy)-7-chloro-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine
US4284555A (en) * 1979-04-27 1981-08-18 Schering Corporation 7-Chloro-8(substituted amino carbonyloxy)-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
US4477378A (en) * 1980-02-05 1984-10-16 Schering Corp. Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines
JPS61267555A (ja) * 1984-11-27 1986-11-27 Dainippon Pharmaceut Co Ltd キノリン誘導体及びそれを有効成分とする抗潰瘍剤
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition

Also Published As

Publication number Publication date
FI902553A0 (fi) 1990-05-23
ZA903895B (en) 1991-03-27
AU623779B2 (en) 1992-05-21
DK0399903T3 (da) 1993-02-08
EP0399903B1 (fr) 1992-12-23
DE69005359D1 (de) 1994-02-03
NO902280D0 (no) 1990-05-23
FR2647343B1 (fr) 1994-05-06
NO180517B (no) 1997-01-27
PT94138B (pt) 1996-12-31
AU631888B2 (en) 1992-12-10
CA2017360A1 (fr) 1990-11-24
NZ233784A (en) 1993-04-28
ZA903978B (en) 1991-03-27
IL94459A0 (en) 1991-03-10
IE901862L (en) 1990-11-24
ES2054289T3 (es) 1994-08-01
GR3006655T3 (no) 1993-06-30
KR0163423B1 (ko) 1998-12-01
IL94459A (en) 1995-01-24
US5244881A (en) 1993-09-14
AU5743390A (en) 1990-12-18
IE901821L (en) 1990-11-24
DE69000641T2 (de) 1993-06-09
NO902280L (no) 1990-11-26
TW257672B (no) 1995-09-21
PT94139A (pt) 1991-01-08
DK0399902T3 (da) 1994-02-14
WO1990014089A1 (fr) 1990-11-29
YU100790A (en) 1992-05-28
PT94139B (pt) 1996-12-31
IE63317B1 (en) 1995-04-05
PT94138A (pt) 1991-01-08
JPH0356412A (ja) 1991-03-12
ES2062437T3 (es) 1994-12-16
NZ233766A (en) 1991-08-27
EP0399903A1 (fr) 1990-11-28
EP0399902A1 (fr) 1990-11-28
FI103712B (fi) 1999-08-31
KR900017570A (ko) 1990-12-19
NO180517C (no) 1997-05-07
DD297915A5 (de) 1992-01-30
CA2017355A1 (fr) 1990-11-24
JP2948271B2 (ja) 1999-09-13
PL285327A1 (en) 1991-02-11
EP0399902B1 (fr) 1993-12-22
IE64370B1 (en) 1995-07-26
ATE98867T1 (de) 1994-01-15
DE69005359T2 (de) 1994-05-05
FI103712B1 (fi) 1999-08-31
AU5582890A (en) 1991-01-10
DE69000641D1 (de) 1993-02-04
ATE83663T1 (de) 1993-01-15
FR2647343A1 (fr) 1990-11-30

Similar Documents

Publication Publication Date Title
IL94460A0 (en) Pharmaceutical compositions containing imipramine or derivatives thereof
IE862554L (en) Pharmaceutical compositions
MY101566A (en) Pharmaceutical compositions.
NO921382D0 (no) Amidinofenylalaninderivater, samt fremstilling, anvendelse og preparater inneholdende forbindelsene
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
FR2674755B1 (fr) Nouvelles compositions medicamenteuses immunostimulatrices.
IL109866A0 (en) Crystalline 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine (+) l-hydrogentartrate, its preparation and pharmaceutical compositions containing it
NO923266L (no) Heksahydrobenzo(f)quinolinoner
HUP9900863A3 (en) 4,4-(disubstituted)cyclohexan-1-ol derivatives pharmaceutical compositions containing these compounds and use thereof
AR008474A1 (es) Derivado de 9-dihidroeritromicina a 6,9; 11,12-diciclocarbonato, composicion farmaceutica y preparacion bactericida que lo contienen y su uso
Seo Recommendations for the Improvement of the Medical Licensing Examination
ZA92192B (en) Pharmaceutical compositions.
GB8918757D0 (en) Substituted 4-azatricyclo(21.3.1.0.4.8)heptacos-17-ene derivate,its preparation and pharmaceutical compositions containing it
GB8918761D0 (en) Substituted 4-azatricyclo(22.3.1.04.9)octacos-18-ene derivate,its preparation and pharmaceutical compositions containing it
GB8918760D0 (en) Substituted 4-azatricyclo(22.3.1.04.9)octacos-18-ene derivate,its preparation and pharmaceutical compositions containing it
MX9200443A (es) Hidrato de 6-ciclohexil-2'-o-metil-adenosina, procedimiento para su preparacion y composicion farmaceutica que los contiene.
IT8821136A0 (it) Composizioni farmaceutiche per la litolisi di calcoli biliari secondari residui o ricorrenti.
IT1258818B (it) Composizioni farmaceutiche orali a base di n5-metiltetraidrofolato di calcio